85 related articles for article (PubMed ID: 36472728)
21. Apalutamide-associated skin rash in patients with prostate cancer: Histological evaluation by skin biopsy.
Tohi Y; Kataoka K; Miyai Y; Kaku Y; Dainichi T; Haba R; Tsunemori H; Sugimoto M
IJU Case Rep; 2021 Sep; 4(5):299-302. PubMed ID: 34497989
[TBL] [Abstract][Full Text] [Related]
22. A Model-Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk.
Sannala CKR; MacLean C; Larsen F; van Os S; Jadhav P; Shore N; Morgans AK; Okwuosa T; Gobburu J
Clin Pharmacol Drug Dev; 2024 May; ():. PubMed ID: 38757461
[TBL] [Abstract][Full Text] [Related]
23. Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer-time for a rethink?
Cabarkapa S; Perera M; Sikaris K; O'Brien JS; Bolton DM; Lawrentschuk N
Prostate Int; 2018 Mar; 6(1):1-6. PubMed ID: 29556482
[TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy and tolerability of abdominal once-yearly histrelin acetate subcutaneous implants in patients with advanced prostate cancer.
Woolen S; Holzmeyer C; Nesbitt E; Siami PF
Prostate Cancer; 2014; 2014():490315. PubMed ID: 25548680
[TBL] [Abstract][Full Text] [Related]
25. Relugolix - The novel oral androgen deprivation therapy for prostate cancer.
Jena R
Indian J Urol; 2020; 36(4):327-328. PubMed ID: 33376275
[No Abstract] [Full Text] [Related]
26. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal N; Azad AA; Carles J; Fay AP; Matsubara N; Heinrich D; Szczylik C; De Giorgi U; Young Joung J; Fong PCC; Voog E; Jones RJ; Shore ND; Dunshee C; Zschäbitz S; Oldenburg J; Lin X; Healy CG; Di Santo N; Zohren F; Fizazi K
Lancet; 2023 Jul; 402(10398):291-303. PubMed ID: 37285865
[TBL] [Abstract][Full Text] [Related]
27. Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.
George DJ; Saad F; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown B; Selby B; Lu S; Buckley D; Tombal B; Shore ND
Clin Genitourin Cancer; 2023 Jun; 21(3):383-392.e2. PubMed ID: 37062659
[TBL] [Abstract][Full Text] [Related]
28. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Chi KN; Rathkopf D; Smith MR; Efstathiou E; Attard G; Olmos D; Lee JY; Small EJ; Pereira de Santana Gomes AJ; Roubaud G; Saad M; Zurawski B; Sakalo V; Mason GE; Francis P; Wang G; Wu D; Diorio B; Lopez-Gitlitz A; Sandhu S;
J Clin Oncol; 2023 Jun; 41(18):3339-3351. PubMed ID: 36952634
[TBL] [Abstract][Full Text] [Related]
29. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis.
Riaz IB; Naqvi SAA; He H; Asghar N; Siddiqi R; Liu H; Singh P; Childs DS; Ravi P; Hussain SA; Murad MH; Boorjian SA; Sweeney C; Van Allen EM; Bryce AH
JAMA Oncol; 2023 May; 9(5):635-645. PubMed ID: 36862387
[TBL] [Abstract][Full Text] [Related]
30. Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.
Cao B; Kim M; Reizine NM; Moreira DM
Eur Urol Oncol; 2023 Jun; 6(3):237-250. PubMed ID: 36682938
[TBL] [Abstract][Full Text] [Related]
31. Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy.
Tatenuma T; Miyamoto H
Drug Des Devel Ther; 2023; 17():2325-2333. PubMed ID: 37559910
[TBL] [Abstract][Full Text] [Related]
32. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
[TBL] [Abstract][Full Text] [Related]
33. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND
Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183
[TBL] [Abstract][Full Text] [Related]
34. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
[TBL] [Abstract][Full Text] [Related]
35. A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer.
De La Cerda J; Dunshee C; Gervasi L; Sieber P; Belkoff L; Tutrone R; Lu S; Gatoulis SC; Brown B; Migoya E; Shore N
Target Oncol; 2023 May; 18(3):383-390. PubMed ID: 37060432
[TBL] [Abstract][Full Text] [Related]
36. Relugolix: A Review in Advanced Prostate Cancer.
Shirley M
Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
[TBL] [Abstract][Full Text] [Related]
37. Relugolix in the management of prostate cancer.
Sahu KK; Tripathi N; Agarwal N; Swami U
Expert Rev Anticancer Ther; 2022 Sep; 22(9):891-902. PubMed ID: 35866612
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
